Investor Information Overview

Corporate Profile

We are an international pharmaceutical company focused on the discovery, development and commercialization of proprietary drugs based on prostones. Prostones are a class of compounds that occur naturally in the human body as a result of enzymatic (15-PGDH) transformation of certain fatty acids. We believe that most prostones function as activators of cellular ion channels. As a result, prostones promote fluid secretion More >>

Stock Quote

SCMP (Common Stock)
Exchange	NASDAQ GM (US Dollar)
Price	$7.92
Change (%)	0.11 (1.37%)
Volume	150,500
Data as of 05/17/12 4:00 p.m. ET Minimum 20 minute delay Refresh quote

Recent News

| More >>

Date	Title
05/09/12	Sucampo Pharmaceuticals, Inc. Reports First Quarter 2012 Financial and Operating Results
05/02/12	Sucampo Announces First Quarter 2012 Financial Results and Operating Highlights Teleconference and Webcast
04/27/12	Sucampo Pharmaceuticals Provides Update on Anticipated Arbitration Decision Date
04/18/12	Sucampo and Clinigen Announce Named Patient Program for European Union, Iceland and Norway to Provide Access to AMITIZA(R) (lubiprostone) for Chronic Idiopathic Constipation Patients

Upcoming Events

Date

Title

05/25/12 8:30 a.m. ET

Sucampo Pharmaceuticals, Inc. Annual Meeting of Shareholders
Location	Hyatt Regency Bethesda Bethesda, MD

Quotes delayed at least 15 minutes. Market data provided by Interactive Data.

Terms & Conditions. Powered and implemented by Interactive Data Managed Solutions.